Precision BioSciences (DTIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The analysts covering Precision BioSciences, Inc. (NASDAQ:DTIL) delivered a dose of negativity to shareholders today...
Precision BioSciences, Inc. (NASDAQ:DTIL) missed earnings with its latest yearly results, disappointing...
Precision BioSciences (DTIL) delivered earnings and revenue surprises of 1.89% and 34.71%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
DURHAM, N.C., Feb. 21, 2020 -- Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering,.
Over the first quarter of 2020, more than $31 billion in value disappeared from the books of local public companies that collectively employ more than a hundred thousand workers in the Triangle and across the U.S.
Shares of Precision BioSciences (NASDAQ:DTIL) rose 8.2% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share rose 73.87% year over year to ($0.52), which were in line with the estimate of ($0.52).Revenue of $6,998,000 rose by 28.12% from the same period last year, which beat the estimate of $4,260,000.Guidance Earnings guidance hasn't been issued by the company for now.View more earnings on DTILPrecision BioSciences hasn't issued any revenue guidance for the time being.Technicals Company's 52-week high was at $23.67Company's 52-week low was at $4.60Price action over last quarter: Up 20.18%Company Description Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The company's segments include Therapeutics and Food.See more from Benzinga * Recap: PBF Logistics Q1 Earnings * Recap: BIO-key International Q4 Earnings * CooTek: Q1 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Just under a year after its debut on public markets, a Durham gene therapy company says it is positioned – scientifically and financially – for a strong 2020.
Precision BioSciences, Inc. (DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS® genome editing platform, announced today that Geno Germano, President and CEO of Elucida Oncology, has been appointed to the company’s Board of Directors. “We welcome him and look forward to working together.”
Despite a strong economy and promising therapeutic candidates, many public companies in the Triangle's life sciences sector saw a difficult year in terms of their stock price while other companies made large exits and rebounds.
DURHAM, N.C., Jan. 06, 2020 -- Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering,.
Precision BioSciences (DTIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DURHAM, N.C., April 15, 2020 -- Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering,.
Precision BioSciences, Inc. (DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS® genome editing platform, today announced the initiation of patient dosing in a Phase 1/2a clinical trial of its second off-the-shelf (allogeneic) chimeric antigen receptor (CAR) T cell therapy candidate, PBCAR20A. The first cohort will enroll patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL), and the second will include patients with R/R chronic lymphocytic leukemia (CLL) or R/R small lymphocytic lymphoma (SLL). The NHL cohort will include patients with mantle cell lymphoma (MCL), an aggressive subtype of NHL, for which Precision BioSciences has received orphan drug designation from the United States Food and Drug Administration (FDA).
DURHAM, N.C., May 26, 2020 -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary.
DURHAM, N.C., May 07, 2020 -- Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering,.
Dosed First Patient in Phase 1/2a Clinical Study of PBCAR20A in Relapsed/Refractory NHL, CLL, and SLL PBCAR0191 Phase 1/2a Trial is Progressing with Updated Interim Data.
Precision BioSciences, Inc. (DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for PBCAR269A, the Company’s third allogeneic chimeric antigen receptor (CAR) T cell therapy candidate. The FDA has also granted Orphan Drug Designation to PBCAR269A for the treatment of multiple myeloma.
-Presented initial clinical data for lead allogeneic CAR T program PBCAR0191 for the treatment of NHL and B-ALL- -Implemented amendment to PBCAR0191 Phase 1/2a trial focused on.
DURHAM, N.C., April 28, 2020 -- Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering,.